- Tirzepatide Dual GIP/GLP-1 agonist; approved (Mounjaro / Zepbound). Robust human
- Retatrutide Triple GGG agonist; Phase 3 weight-loss data flagged topline. Limited human (topline)
- GHK-Cu Copper tripeptide; topical evidence only, systemic untested. Human topical/local only
- Thymosin β4 (TB4) Phase 2/3 local trials; mixed dry-eye results. Human topical/local only
- KPV α-MSH-derived tripeptide; no human trials. Preclinical only
- BPC-157 Pentadecapeptide; animal data from one group, no human trials. Preclinical only
- TB-500 Thymosin β4 fragment; injected use untested in humans. Preclinical only
- AOD-9604 hGH fragment; failed its pivotal obesity trial. Contested / negative
Grades follow the charter rubric. A higher grade means stronger evidence, not a recommendation; this resource recommends nothing.